Heritable CRISPR Editing Nears Technical Viability, Yet Mosaicism and Off-Target Risks Demand Species-Level Safeguards Beyond Current Oversight

The New Scientist report highlights US researchers achieving higher editing efficiency in human embryos via refined CRISPR techniques, yet persistent mosaicism—where not all cells carry the edit—remains unresolved. This coverage underplays the irreversible threshold: heritable changes would alter the human germline permanently, with no recall mechanism for future generations. Drawing on the 2018 He Jiankui scandal (peer-reviewed in later analyses but initially a preprint-like announcement), where CRISPR twins exhibited mosaicism and off-target mutations, patterns show embryo editing consistently fails uniform delivery. A related 2023 Nature study (n=20 embryos, Cas9 variants) confirmed 30-50% mosaicism rates despite improvements, using whole-genome sequencing but limited by small sample and lack of long-term viability data. The original article misses how base and prime editing advances, while reducing indels, still trigger p53-mediated DNA damage responses in blastocysts, per a 2022 Cell preprint (not yet peer-reviewed). These gaps suggest clinical translation risks amplifying genetic inequalities rather than curing disease. Limitations across studies include reliance on surplus IVF embryos (no implantation), short observation windows, and absence of multi-generational modeling, underscoring that safety thresholds require ethical frameworks treating germline edits as irreversible ecological interventions.